Safety and efficacy of oxycodone/naloxone vs. oxycodone vs. morphine for the treatment of chronic low back pain: results of a 12 week prospective, randomized, open-label blinded endpoint streamlined study with prolonged-release preparations

References

• Breivik H, Collett B, Ventafridda V. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006;10:287-333
   PubMed Web of Science ®Google Scholar
• Reid KJ, Harker J, Bala MM, et al. Epidemiology of chronic non-cancer pain in Europe: narrative review of prevalence, pain treatments and pain impact. Curr Med Res Opin 2011;27:449-62
   PubMed Web of Science ®Google Scholar
• Sng BL, Schug SA. The role of opioids in managing chronic non-cancer pain. Ann Acad Med Singapore 2009;38:960-6
   PubMed Web of Science ®Google Scholar
• Wiffen PJ. Evidence-based pain management and palliative care in issue one for 2005 of The Cochrane Library. J Pain Palliat Care Pharmacother 2005;19:65-8
   PubMedGoogle Scholar
• Caraceni A, Hanks G, Kaasa S, et al., European Palliative Care Research Collaborative (EPCRC), European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012;13:e58-68
   PubMed Web of Science ®Google Scholar
• Ahmedzai SH, Nauck F, Bar-Sela G, et al. A randomized, double-blind, active-controlled, double-dummy, parallel group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 2012;26:50-60
   PubMed Web of Science ®Google Scholar
• Chou R, Huffman LH, American Pain Society, American College of Physicians. Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med 2007;147:505-14
   PubMed Web of Science ®Google Scholar
• Kahan M, Mailis-Gagnon A, Wilson L, Srivastava A, National Opioid Use Guideline Group. Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 1: general population. Can Fam Physician 2011;57:1257-66
   PubMed Web of Science ®Google Scholar
• Häuser W, Bock F, Engeser P, et al. S3 guideline for the long-term use of opioids in non-cancer pain. Dtsch Arztebl Int 2014;111:732-40
   PubMed Web of Science ®Google Scholar
• Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001;182:11-18S
   PubMed Web of Science ®Google Scholar
• Coluzzi F, Pappagallo M. Opioid therapy for chronic noncancer pain: practice guidelines for initiation and maintenance of therapy. Minerva Anestesiol 2005;71:425-33
   PubMedGoogle Scholar
• Bell TJ, Panchal SJ, Miaskowski C, et al. The prevalence, severity and impact of opioid-induced bowel dysfunction: results of a US and European patient survey (PROBE 1). Pain Med 2009;10:35-42
   PubMed Web of Science ®Google Scholar
• Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003;63:649-71
   PubMed Web of Science ®Google Scholar
• Becker G, Galandi D, Blum HE. Peripherally acting opioid antagonists in the treatment of opiate-related constipation: a systematic review. J Pain Symptom Manage 2007;34:547-65
   PubMed Web of Science ®Google Scholar
• Panchal SJ, Mueller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract 2007;61:1181-7
   PubMed Web of Science ®Google Scholar
• Odegard PS, Burke C. Managements of opioid induced constipation in elderly patients. Consultant Pharmacist 1996;11:17-22
   Google Scholar
• Leppert W. The role of opioid receptor antagonists in the treatment of opioid-induced constipation: a review. Adv Ther 2010;27:714-30
   PubMed Web of Science ®Google Scholar
• Mercadante S, Giarratano A. Combined oral prolonged-release oxycodone and naloxone in chronic pain management. Expert Opin Investig Drugs 2013;22:161-6
   PubMed Web of Science ®Google Scholar
• Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009;13:56-64
   PubMed Web of Science ®Google Scholar
• Löwenstein O, Leyendecker P, Hopp M, et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother 2009;10:531-43
   PubMed Web of Science ®Google Scholar
• Löwenstein O, Leyendecker P, Lux EA, et al. Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials. BMC Clin Pharmacol 2010;10:1-9
   PubMedGoogle Scholar
• Vondrackova D, Leyendecker P, Meissner W, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 2008;9:1144-54
   PubMed Web of Science ®Google Scholar
• Sandner-Kiesling A, Leyendecker P, Hopp M, et al. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract 2010;64:1-12
   PubMed Web of Science ®Google Scholar
• Ahmedzai SH, Leppert W, Janecki M, et al. Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain. Support Care Cancer 2015;23:823-30
   PubMed Web of Science ®Google Scholar
• Blagden M, Hafer J, Duerr H, et al. Long-term evaluation of combined prolonged-release oxycodone and naloxone in patients with moderate-to-severe chronic pain: pooled analysis of extension phases of two phase III trials. Neurogastroenterol Motil 2014;26:1792-801
   PubMed Web of Science ®Google Scholar
• Schutter U, Grunert S, Meyer C, et al. Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice. Curr Med Res Opin 2010;26:1377-87
   PubMed Web of Science ®Google Scholar
• Kassenärztliche Bundesvereinigung, Arzneimittelkommission der Deutschen Ärzteschaft. Oxycodon/Naloxon. Wirkstoff Aktuell 2012;6
   Google Scholar
• Böger RH, Schmidt G. Analgetika. In: Schwabe U, Paffrath D (eds.): Arzneiverordnungsreport 2014. Berlin, Heidelberg, Springer: 2014:301-19
   Google Scholar
• Hansson L, Hedner T, Dahlöf B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Blood Press 1992;1:113-19
   PubMedGoogle Scholar
• Cryer B, Li C, Simon LS, et al. GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial. Am J Gastroenterol 2013;108:392-400
   PubMed Web of Science ®Google Scholar
• Deutsche Schmerzgesellschaft. Deutscher Schmerzfragebogen [German pain questionnaire]. Available at: http://www.dgss.org/deutscher-schmerzfragebogen [Last accessed 10 April 2015]
   Google Scholar
• Deutsche Schmerzgesellschaft. Handbuch zum Deutschen Schmerzfragebogen [Manual for the German pain questionnaire]. Available at: http://www.dgss.org/fileadmin/pdf/12_DSF_Manual_2012.2.pdf [Last accessed 10 April 2015]
   Google Scholar
• Rentz AM, Yu R, Mueller-Lissner S, Leyendecker P. Validation of the bowel function index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ 2009;12:371-83
   PubMedGoogle Scholar
• Ueberall MA, Mueller-Lissner S, Buschmann-Kramm C, Bosse B. The bowel function index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients. J Int Med Res 2011;39:41-50
   PubMed Web of Science ®Google Scholar
• Frettlöh J, Maier C, Gockel H, Hüppe M. Validation of the German Mainz Pain Staging System in different pain syndromes. Schmerz 2003;17:240-51
   PubMed Web of Science ®Google Scholar
• Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of chronic pain. Pain 1992;50:133-49
   PubMed Web of Science ®Google Scholar
• Poelaert J, Koopmans-Klein G, Dioh A, et al. Treatment with prolonged-release oxycodone/naloxone improves pain relief and opioid-induced constipation compared with prolonged-release oxycodone in patients with chronic severe pain and laxative-refractory constipation. Clin Ther 2015;37:784-92
   PubMed Web of Science ®Google Scholar
• Levine JD, Gordon NC, Fields HL. Naloxone dose dependently produces analgesia and hyperalgesia in postoperative pain. Nature 1979;278:740-1
   PubMed Web of Science ®Google Scholar
• Rochford J, Stewart J. Activation and expression of endogenous pain control mechanisms in rats given repeated nociceptive tests under the influence of naloxone. Behav Neurosci 1987;101:87-103
   PubMed Web of Science ®Google Scholar
• Greeley J, Le AD, Poulos CX, Cappel H. ‘Paradoxical’ analgesia induced by naloxone and naltrexone. Psychopharmacology 1988;96:36-9
   PubMed Web of Science ®Google Scholar
• Poulos CX, Knoke DM, Le AD, Cappell H. Naloxone-induced analgesia and morphine supersensitivity effects are contingent upon prior exposure to analgesic testing. Psychopharmacology 1990;100:31-5
   PubMed Web of Science ®Google Scholar
• Wang H-Y, Friedman E, Olmstead MC, Burns LH. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu-opioid receptor – G protein coupling and Gβγ signaling. Neuroscience 2005;135:247-61
   PubMed Web of Science ®Google Scholar
• Burns L, Wang H-Y. Ultra-low-dose naloxone or naltrexone to improve opioid analgesia: the history, the mystery and a novel approach. Clinical Medicine Insights: Therapeutics 2010;2:857-68
   Google Scholar
• Kohro T, Yamazaki T. Cardiovascular clinical trials in Japan and controversies regarding prospective randomized open-label blinded end-point design. Hypertens Res 2009;32:109-14
   PubMed Web of Science ®Google Scholar